FLAMMA receives ICCF Award for investments made at Flamma Honkai
Chignolo D’Isola, Bergamo, Italy – December 14, 2023 – The Flamma Group (“Flamma”), a global, fully integrated company producing and commercializing small molecule Active Pharmaceutical Ingredients (APIs) for the life science industry as well as a preeminent Contract Development and Manufacturing Organization (CDMO) of New Chemical Entities (NCEs) and late stage intermediates for the Innovator Companies, was recently recognized by the Italy China Council Foundation (ICCF) for being a Top Investor in China . The event which had over 250 guests included many personalities from the world of culture, sport and entertainment.
“The China Awards are now a traditional event, which Class Editori has been organizing for years with what was once the Italy China Foundation and is now the Italy China Council Foundation”, said Paolo Panerai, Publisher and CEO of Class Editori.
“This is a unique event, and a very specific point of reference in relations between Italy and China, because it is rewarding companies from the two countries for their cross-economic activity and is equivalent to promoting development and harmony between their respective peoples”.
Early in 2023, Flamma announced the commitment to invest $250M over the next three years. Included in this investment was a significant investment at Flamma Honkai to complete a new GMP facility. The investment will increase Flamma Honkai’s capacity from 200 m3 of small molecule API/NCE capacity to initially 400 m3 and then ultimately to 600 m3. Additionally, new technologies will be added to the site such as flow technology
Gianmarco Negrisoli, Executive Director, stated, “Flamma is thankful for this recognition from the ICCF. We will continue our mission to provide value to the companies that we work with. We will do our part to bring new and innovative drugs to the global pharmaceutical marketplace.”